Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
Summary not available.
BioRestorative Therapies (NASDAQ:BRTX) has appointed Robert Paccasassi as Vice President of Quality Assurance/Regulatory Compliance. With over 25 years of experience in biotech and quality systems, he will oversee quality initiatives as the company begins patient enrollment for a Phase 2 clinical trial targeting chronic lumbar disc disease. Paccasassi’s past roles include significant positions at Merck KGaA, Regeneron, Millennium, and Biogen Idec. This leadership appointment aims to enhance the company's compliance and quality control in its stem cell therapy programs.
BioRestorative Therapies (BRTX) will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, scheduled virtually from January 10-13, 2022. CEO Lance Alstodt will lead a pre-recorded presentation available starting January 10 at 7 a.m. ET. Attendees can access the link for the presentation here. The presentation will also be archived for 30 days on the company’s website. BRTX focuses on stem cell-based treatments, including the brtxDISC™ program for spine disease and the ThermoStem® program targeting metabolic disorders.
BioRestorative Therapies announced a Phase I STTR grant of $256,000 from the NIH to evaluate the therapeutic effects of its hypoxic cultured bone marrow-derived stem cells (BRTX-100) with a novel PEG-peptide hydrogel. This collaboration with Dr. Lori Setton aims to optimize therapeutic delivery methods. Successful completion of this phase could lead to applications for Phase II funding, potentially reaching $1 million. The grant demonstrates recognition of BioRestorative's innovative approach to stem cell therapies, particularly in treating chronic lower back pain.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has signed a Master Service Agreement with PRC Clinical to manage its Phase 2 clinical trial for BRTX-100, aimed at treating chronic lumbar disc disease. PRC Clinical brings extensive experience and innovative technology to the collaboration. CEO Lance Alstodt emphasized this partnership as a significant step towards clinical development. The trial's success could advance BioRestorative's mission to develop cell-based therapeutics, as they aim for primary endpoint readouts in the near future.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced that CEO Lance Alstodt will appear on the NewMedia Show on December 21, 2021. The show features discussions on various topics, leveraging a broad audience across social media platforms, including YouTube and LinkedIn. Alstodt expressed excitement to share the company’s 2021 achievements and future plans. BioRestorative specializes in adult stem cell-based therapies and is developing treatments for disc/spine disease and metabolic disorders, notably BRTX-100 for chronic lower back pain.
BioRestorative Therapies (NASDAQ: BRTX) recently shared a year-end update reflecting on 2021's achievements and 2022 goals. The company raised $23 million through a capital raise, enabling it to fund its Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease. Major milestones included uplisting to the Nasdaq, eliminating all debt, and restructuring operations. Looking ahead, BioRestorative aims to enroll patients for the BRTX-100 trial and further develop its products, particularly its ThermoStem® program.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has filed ten patent applications with the USPTO relating to its BRTX-100 program aimed at treating chronic lumbar disc disease. The patents focus on manufacturing methods for stem cells that can survive in low-oxygen environments, crucial for effective therapy. This strengthens the company's intellectual property portfolio. BioRestorative is FDA-authorized to begin a Phase 2 clinical trial for BRTX-100.
BioRestorative Therapies (NASDAQ:BRTX) has signed a letter of intent with PRC Clinical to provide startup CRO services for its BRTX-100 Phase 2 trial. This trial aims to treat chronic lumbar disc disease using an innovative stem cell therapy. PRC Clinical brings 20 years of experience in clinical trial management, enhancing patient enrollment and site monitoring. The collaboration marks a significant step towards FDA validation of their technology. CEO Lance Alstodt highlighted the importance of this partnership in updating shareholders throughout the regulatory process.
BioRestorative Therapies (NASDAQ:BRTX) announces the appointment of Robert Kristal as Chief Financial Officer. Kristal, with extensive experience in corporate finance and strategic collaborations, aims to enhance the company's financial strategy and communication with public markets. His role comes at a critical time as BioRestorative prepares to initiate clinical trials following a successful restructuring into a debt-free entity. The company is focused on developing innovative therapies, notably BRTX-100 for disc disorders and ThermoStem for metabolic conditions.